Novo Nordisk has announced a strategic move to broaden patient access in the U.S. market. Starting January 1, 2027, the list price for its popular medications—Wegovy, Ozempic, and Rybelsus—will be standardized at $675 per month. This reduction specifically targets patients on high-deductible health plans and coinsurance designs, effectively lowering out-of-pocket costs that are directly linked to the drug’s list price.
The price adjustment applies to several key dosages, including Wegovy 2.4 mg injections and 25 mg tablets; Ozempic injections (0.5 mg, 1 mg, and 2 mg); and Rybelsus tablets ranging from 7 mg to 14 mg. Alongside these pricing changes, Novo Nordisk achieved a significant milestone in Europe with the European Commission’s approval of a higher maintenance dose (7.2 mg) for injectable Wegovy, enabling patients to achieve an average weight loss of approximately 21%.
This proactive list price reduction comes as competition in the GLP-1 space intensifies, notably with Eli Lilly preparing for a massive launch of its drug orforglipron. To protect its market position and patient safety, Novo Nordisk has also ramped up legal actions to prevent the sale of unapproved, compounded “knock-off” versions of its drugs, reaffirming its commitment to the FDA’s gold standard review process.
Source: https://www.pharmexec.com/view/novo-nordisk-significant-price-drops-popular-glp1-medications